Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)

PHASE2CompletedINTERVENTIONAL

Enrollment

557

Participants

Timeline

Start Date

February 21, 2006

Primary Completion Date

August 31, 2007

Study Completion Date

September 24, 2007

Conditions

Urinary IncontinenceOveractive Bladder

Interventions

DRUG

MK0594

All Listed Sponsors

lead

Vyne Therapeutics Inc.

INDUSTRY

NCT00290563 - Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003) | Biotech Hunter | Biotech Hunter